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Epidermal growth factor receptor (EGFR) signaling is fundamentally important for tissue homeostasis through
EGFR/ligand interactions that stimulate numerous signal transduction pathways. Aberrant EGFR signaling has
been reported in inflammatory and malignant diseases, but thus far no primary inherited defects in EGFR have
been recorded. Using whole-exome sequencing, we identified a homozygous loss-of-function missense
mutation in EGFR (c.1283G4A; p.Gly428Asp) in a male infant with lifelong inflammation affecting the skin,
bowel, and lungs. During the first year of life, his skin showed erosions, dry scale, and alopecia. Subsequently,
there were numerous papules and pustules—similar to the rash seen in patients receiving EGFR inhibitor drugs.
Skin biopsy demonstrated an altered cellular distribution of EGFR in the epidermis with reduced cell membrane
labeling, and in vitro analysis of the mutant receptor revealed abrogated EGFR phosphorylation and EGF-
stimulated downstream signaling. Microarray analysis on the patient’s skin highlighted disturbed differentiation/
premature terminal differentiation of keratinocytes and upregulation of several inflammatory/innate immune
response networks. The boy died at the age of 2.5 years from extensive skin and chest infections as well as
electrolyte imbalance. This case highlights the major mechanism of epithelial dysfunction following EGFR
signaling ablation and illustrates the broader impact of EGFR inhibition on other tissues.
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INTRODUCTION
EGFR signaling represents a key activity in several biological
processes underpinning tissue development and homeostasis
(Jutten and Rouschop, 2014). Thus far, seven EGFR ligands
have been identified: EGF, transforming growth factor-a,
amphiregulin, heparin-binding EGF-like growth factor, beta-
cellulin, epiregulin, and epigen (Schneider and Wolf, 2009;
Nanba et al., 2013). Interaction between EGFR and these
ligands leads to stimulation of numerous transduction
pathways that include the RAS/RAF/MEK/ERK, PLC-g/PKC,
PI3K/AKT, JAK/STAT, and NF-kB cascades (Jost et al., 2000;
Sibilia et al., 2007). Acquired abnormalities of EGFR signaling
have been observed in various inflammatory and malignant
diseases (Jost et al., 2000; Gschwind et al., 2004; Dreux et al.,
2006; Zhang et al., 2014). Of note, aberrant EGFR activation is
found in many tumor cells, and humanized neutralizing
antibodies and synthetic small compounds against EGFR are
in clinical use today. These drugs may cause skin and hair
toxicities, indicating a key role for EGFR in cutaneous
homeostasis (Lacouture, 2006; Liu et al., 2013). These side
effects have been recapitulated in a mouse model, with
evident abnormalities in cutaneous chemokines associated
with early infiltration of macrophages and mast cells and later
infiltration of eosinophils, T cells, and neutrophils (Mascia
et al., 2013). EGFR mutations in tumors are typically gain of
function and located within the tyrosine kinase domain of the
protein, but thus far there are no reports of naturally occurr-
ing loss-of-function mutations in humans. Knockout and trans-
genic murine models and in vitro studies have demonstrated
the essential role of EGFR in multiple organs (Miettinen et al.,
1995; Sibilia and Wagner, 1995; Threadgill et al., 1995; Jost
et al., 2000; Schneider et al., 2008), but clinical correlates in
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patients are currently lacking. In this study, we used whole-
exome sequencing to identify an inherited loss-of-function
mutation in EGFR in an individual with inflammatory skin,
lung, and bowel disease.
RESULTS AND DISCUSSION
Clinical presentation with cutaneous erosions and inflammation
We investigated a male infant born to parents of Polish Roma
origin who presented to us at 12 months of age with extensive
skin inflammation. Initially, there were widespread erosions
affecting his trunk and limbs that had been present since birth
(Figure 1a), but subsequently we observed papules and
pustules (Figure 1b). He also had lifelong watery diarrhea
and respiratory difficulties. He was born at 34 weeks of
gestation, weighing 1,560 g; the pregnancy had been compli-
cated by polyhydramnios and maternal hypertension. Clini-
cally, at 12 months his weight was only 5.52 kg with evident
failure to thrive. His inflamed skin was frequently infected
with Staphylococcus aureus. He had loss of scalp hair but
long eyelashes (trichomegaly). No nail abnormalities were
observed. He had previously undergone surgery for probable
coarctation of the aorta and was noted to be hypertensive.
Other abnormalities included recurrent bronchiolitis and
pulmonary infection with Pseudomonas aeruginosa (requiring
tracheostomy and oxygen). Renal ultrasound showed bilateral
renal enlargement but no obstruction. The child had no
specific food allergies but was unable to tolerate solids
due to diarrhea and vomiting and severe dehydration.
We observed low albumin, zinc, vitamin A, iron, magnesium,
profound hypokalemia (persistent), and hypernatremia,
although barium meal showed no evidence of malabsorption.
He preferred to drink water rather than milk and subsequently
required total parenteral nutrition. Blood eosinophil counts
were slightly elevated during the first year (observed levels:
0.4–1.0109 l 1). Total IgE was found to be raised as a
neonate (100 IU l1; range for o1 year: 0–15 IU l1) and at
15 months (107 IU l1; range for this age: 0–60 IU l1). IgM
was borderline normal/low; IgG and IgA were normal. Venous
access lines frequently became clotted and he developed deep
vein thromboses. He died at the age of 2.5 years as a result of
cutaneous and pulmonary infections and electrolyte imbal-
ance. Further details of the clinical history can be found in the
Supplementary Material online.
Skin biopsy reveals acanthosis and intra-epidermal edema
We obtained written informed consent from the subject’s legal
guardian with approval from the St Thomas’ Hospital Ethics
Committee. Elliptical skin biopsies were obtained under local
anesthetic from a non-lesional area on the right thigh of the
child (aged 12 months) as well as from the abdomens of
healthy control patients undergoing cosmetic (‘‘tummy tuck’’)
surgery. The initial clinical diagnosis was a subtype of
inherited skin fragility, a heterogenous group of disorders
known collectively as epidermolysis bullosa (Fine et al.,
2008). Light microscopy of non-lesional skin revealed mild
acanthosis compared with age- and site-matched control skin,
as well as a slight widening between adjacent keratinocytes
(Figure 2a). A few neutrophils were noted within the super-
ficial dermis with some infiltration of follicular epithelium and
folliculitis, although Gram stain for bacteria was negative. The
changes within the epidermis resembled those of a primary
inherited abnormality of desmosomes (Petrof et al., 2012),
although transmission electron microscopy showed intercel-
lular edema from the basal layer to the mid-spinous layer and
a slight decrease in the number of gap junctions but no
structural or numerical abnormalities in hemidesmosome or
desmosome cell junctions (Figure 2b). Skin immunolabeling
using a panel of antibodies that target basement membrane
and epidermal proteins implicated in inherited skin fragility
disorders (see Supplementary Material online for antibody
details) demonstrated a marked reduction in staining intensity
for the desmosomal proteins desmoglein 1 and plakophilin 1,
as well as altered labeling patterns for profilaggrin, involucrin,
and keratin 10, markers of terminal differential in the epider-
mis (illustrated in Supplementary Material online). Some of
the clinicopathologic features also resembled Netherton
syndrome, an autosomal recessive disorder associated with
loss-of-function mutations in a serine protease inhibitor
(SPINK5) that encodes lympho-epithelial Kazal-type-related
12 Months
22 Months
Figure 1. Clinical features of the patient demonstrating inflammation,
erosions, papules, and pustules. (a) At 12 months of age, the infant has
extensive erosions and markedly reduced scalp hair and eyebrows. He is also
receiving total parenteral nutrition. (b) At 22 months, there is a confluent
papular eruption, particularly on the limbs, with numerous pustules. Consent to
publish these photographs was obtained from the infant’s mother.
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inhibitor (Chavanas et al., 2000; Stoll et al., 2001). Immuno-
staining for lympho-epithelial Kazal-type-related inhibitor
in our patient’s skin, however, revealed a slight increase
compared with control (illustrated in Supplementary Material
online), which is in contrast to findings of reduced lympho-
epithelial Kazal-type-related inhibitor expression that usually
accompany Netherton syndrome. Taken together, these find-
ings were not in keeping with any known form of epidermo-
lysis bullosa, Netherton syndrome, or any other recognized
inherited or acquired skin disease.
Whole-exome sequencing reveals a homozygous missense
mutation in EGFR
Next, after obtaining approval from the ethics committee and
informed consent, we extracted genomic DNA from periph-
eral blood samples from the child, other family members, and
controls in compliance with the Declaration of Helsinki
Principles. Using the patient’s DNA, whole-exome sequencing
was performed on the Illumina HiSeq 2000 (Illumina,
San Diego, CA). After excluding pathogenic mutations in
genes implicated in different forms of epidermolysis bullosa
(Fine et al., 2008), the exome variant profile was filtered to
look for novel homozygous mutations (based on probable
consanguinity). This disclosed six possible gene mutations (see
Supplementary Material online). Within these genes, EGFR
was deemed to be of potential relevance, given that some
clinical features (e.g., papulo-pustular skin eruptions,
alopecia, and trichomegaly) resembled known side effects of
EGFR inhibitor drugs (Lacouture, 2006). Immunofluorescence
microscopy to assess EGFR expression in the affected
infant’s skin showed a markedly altered staining pattern with
loss of the cell peripheral membrane labeling and a more
cytoplasmic or perinuclear region distribution compared with
strong cell membrane localization of EGFR throughout the
epidermis, with minimal intracellular labeling, in control skin
(Figure 2c). The nonsynonymous substitution identified in
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Figure 2. The homozygous mutation p.Gly428Asp results in acanthosis, intra-epidermal edema, and loss of keratinocyte cell membrane labeling for EGFR.
(a) Semi-thin section of patient skin from the thigh reveals acanthosis and hyperkeratosis compared with age- and site-matched control skin (scale bar¼ 50mm).
(b) Ultrastructurally, there is widening of spaces between adjacent keratinocytes in the lower epidermis (asterisks; scale bar¼ 2mm). (c) Immunostaining for EGFR
in patient epidermis shows loss of keratinocyte membrane staining compared with control skin (scale bar¼ 50mm). (d) Sanger sequencing reveals a homozygous
missense mutation in EGFR. (e) Schematic representation of the functional domains and encoding exons and the site of the pathogenic mutation in this patient. TM,
transmembranous domain.
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exon 11 of EGFR, c.1283G4A, replaces a neutral glycine
with a negatively charged aspartic acid molecule at a highly
conserved residue, p.Gly428Asp. The pathogenicity of this
missense mutation was supported by both the ‘‘Sorts Intolerant
From Tolerant’’ (score 0, probably damaging) and Polymorph-
ism Phenotyping v2 (score 1, probably damaging) programs
(Ng and Henikoff, 2003; Adzhubei et al., 2010). The EGFR
mutation was also validated by Sanger sequencing (Figure 2d;
primers for EGFR amplification are given in Supplementary
Material online) and found to be homozygous in the affected
patient, heterozygous in the mother, and a homozygous wild-
type sequence in the unaffected older sibling; DNA from the
father was not available. The mutation is located in extra-
cellular domain III of EGFR (Figure 2e), in contrast to the
tyrosine kinase domain mutations commonly found in tumors
(Kumar et al., 2008). The region surrounding the mutation
has been postulated to be involved in intramolecular
interactions that promote dimerization of EGFR and receptor
activation (Ogiso et al., 2002; Dawson et al., 2005). We were
unable to find the observed mutation in the dbSNP database,
the 1,000 Genomes database, the 13,005 exomes in the Exome
Variant Server, or in 900 unrelated European in-house control
exomes.
Aberrant cutaneous expression of genes germane to keratinocyte
differentiation, inflammatory response, and innate immunity
Microarray data have been deposited in the Gene Expression
Omnibus repository; accession number GSE54162. Compar-
ison of the affected infant’s skin with healthy control skin
identified 2-fold or greater differential expression for 2,157
gene transcripts: 1,004 upregulated and 1,153 downregulated.
These genes did not include EGFR, which was insignificantly
upregulated in the patient’s skin (fold change¼ 1.36;
P¼0.012). Evaluation of the changes in gene expression
by functional enrichment analysis identified a multitude of
enriched gene ontology pathways, processes, networks, and
disease-associated transcripts germane to EGFR signaling (see
Supplementary Materials online for tabulated results). The top
three upregulated gene ontology processes were linked to
known EGFR functionality: keratinocyte differentiation, kera-
tinization, and epidermis development (involving genes such
as transglutaminases, small proline-rich genes, S100 genes,
involucrin, and late cornified envelope genes). Reports have
also indicated a role for EGFR in regulating skin inflammation
and cutaneous defense (Lichtenberger et al., 2013; Mascia
et al., 2013). Thus, innate inflammatory response gene com-
ponents (specifically, PLA2, NF-kB, and JNK1) were among
the most significantly upregulated gene ontology networks.
Notably, CCL2 expression was increased 2.2-fold, in keeping
with reported findings in mouse models lacking epidermal
Egfr expression (Lichtenberger et al., 2013). In addition, regula-
tion of epithelial-to-mesenchymal transition and angiogenesis,
processes known to be controled by EGFR activation
(Perrotte et al., 1999; Avraham and Yarden, 2011), were
identified as significantly downregulated gene ontology
pathways and processes, respectively. Of note, there was
also downregulation of transcripts that are normally increased
in tumors that show gain-of-function mutations in EGFR
(e.g., non-small cell lung cancer, colorectal cancer, and
glioblastoma).
Mutant EGFR at the plasma membrane is highly unstable and
more susceptible to constitutive endocytosis
To determine whether the mutation p.Gly428Asp in EGFR was
responsible for mislocalization of EGFR in the affected infant,
we generated DNA constructs containing a mutant or wild-
type EGFR sequence linked to green fluorescent protein (GFP)
and expressed these constructs in MCF-7 cells that express low
endogenous EGFR and analyzed EGF-dependent localization
of EGFR using confocal microscopy. Under normal growth
conditions, the mutant EGFR construct localized diffusely
throughout the cytoplasm of the cell in contrast to the wild-
type construct, which was present mostly on the plasma
membrane (Figure 3a). EGF stimulation resulted in robust
translocation of wild-type EGFR to the plasma membrane
within 10 minutes of EGF treatment (Figure 3b). Conversely,
the mutant EGFR remained in the cytoplasm following
EGF stimulation with no clear recruitment to the plasma
membrane (Figure 3b), suggesting that this mutation prevents
or diminishes EGFR membrane localization, supporting the
immunostaining findings in patient skin (Figure 2c).
EGFR membrane localization is regulated through a balance
of endocytosis under the control of a number of intracellular
signaling pathways that converge on the large GTPase
dynamin (Lee et al., 2006). To examine whether the lack of
mutant EGFR localization to the cell membrane was due to
defective endocytic traffic, MCF-7 cells expressing either wild-
type or mutant EGFR were treated with an inhibitor of
dynamin-mediated endocytosis, Dynasore (Macia et al.,
2006). Receptor localization was then examined by confocal
microscopy. In the absence of ligand, membrane localization
of both wild-type and mutant EGFR increased after treatment
with Dynasore (Figure 3c). Similar results were observed in a
normal human keratinocyte cell line expressing wild-type or
mutant EGFR (see Supplementary Material online). Immunos-
taining of MCF-7 cells expressing wild-type or mutant EGFR
was performed using an antibody against the extracellular
domain of EGFR to quantify membrane localization. Pearson’s
correlation coefficient analysis to quantify the colocalization
between wild-type or mutant EGFR with the antibody staining
demonstrated that for both constructs the EGFR membrane
localization increased significantly following Dynasore treat-
ment (Figure 3c) but not following treatment with the chemical
chaperone sodium 4-phenylbutyrate (4-PBA) (data not shown).
These data demonstrate that the mutant EGFR is able to
undergo recycling to the plasma membrane but that it can
only be retained at the membrane upon blockade of endocytic
signaling. This suggests that the mutation p.Gly428Asp renders
EGFR at the plasma membrane highly unstable and thus more
susceptible to constitutive endocytosis.
Loss of downstream Akt and ERK signaling associated with
mutant EGFR
Following EGF binding, EGFR undergoes rapid autophosphor-
ylation and activation at a number of residues within the
cytoplasmic domain of the receptor. These changes result in
P Campbell et al.
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recruitment of a host of initiators and scaffolds of signaling
leading to activation of MAP kinase family members including
extracellular signal–regulated kinase (ERK; p44/42) and
protein kinase B (Akt; Avraham and Yarden, 2011). We
therefore assessed the effect of the mutation p.Gly428Asp on
EGF-dependent phosphorylation of EGFR and downstream
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Figure 3. The mutation in EGFR renders the receptor unstable and susceptible to endocytosis. (a) Confocal microscopy was performed using green fluorescent
protein (GFP)-tagged constructs of wild-type (WT) or mutant EGFR (green) and F-actin (red) in MCF-7 cells under normal growth conditions. (b) Images were then
taken following stimulation of the cells with EGF at specified time points to assess the localization of EGFR within the cell cytoplasm or at the cell membrane.
(c) Confocal microscope images were also taken for WT and mutant EGFR-GFP constructs (green) in cells stained for surface EGFR (red) in DMSO control or
Dynasore-treated cells (to inhibit endocytosis). The colocalization between EGFR antibody staining and either WT or mutant EGFR-GFP constructs was then
quantified in DMSO control or Dynasore-treated cells using Pearson’s correlation coefficient (panel d). *Po0.001 vs WT-EGFR; scale bar¼ 10mm.
P Campbell et al.
Inherited Mutation in EGFR
2574 Journal of Investigative Dermatology (2014), Volume 134
signaling. EGF-dependent ERK and Akt activation were
assessed in untransfected MCF-7 cells or those expressing
wild-type or mutant EGFR. EGF-stimulated activation of EGFR
(monitored by a phospho-specific antibody) was robust in the
cells expressing wild-type EGFR, but was undetectable in
the mutant EGFR-expressing cells above levels seen in
untransfected controls (Figure 4a). Similarly, neither Akt nor
ERK activation was detected following ligand binding in
mutant EGFR-expressing cells, in contrast to cells expressing
wild-type EGFR, which showed robust EGF-stimulated EGFR,
ERK, and Akt phosphorylation (Figure 4a). We observed
similar results in parallel experiments in another cell line
(CHO-K1 cells; see Supplementary Material online for data).
The observed suppression of EGFR-dependent activation
and downstream signaling suggests that the EGFR mutation
p.Gly428Asp results in loss of function as well as loss of
plasma membrane localization. One of the primary functions
of EGFR signaling following EGF binding is to promote cell
proliferation (Jost et al., 2000). To determine whether the loss
of EGF-dependent signaling in p.Gly428Asp mutant EGFR-
expressing cells results in functional defects, proliferation was
analyzed in CHO-K1 cells expressing the wild-type or mutant
EGFR constructs. EGF and serum-stimulated proliferation was
induced in CHO-K1 cells expressing wild-type EGFR, but no
induction of cell growth was detected in cells expressing the
mutant EGFR (Figure 4b). Indeed, there was a negative growth
rate of the mutant EGFR-expressing cells, consistent with other
work showing that the inhibition of EGFR signaling induces
apoptosis in keratinocytes (Figure 4c; Rodeck et al., 1997).
Clinicopathologic overlap with patients harboring mutations in
ADAM17
The exact mechanism by which the missense mutation
p.Gly428Asp leads to loss of EGFR function is unclear.
Mutagenesis of the adjacent amino acid (p.Arg429Glu) was
previously found to prevent EGFR homodimerization through
disruption of an interface between domains II and III of the
protein (Dawson et al., 2005). However, altered homodimeri-
zation would not provide a sufficient explanation for the
pathology as both monomeric EGFR and the p.Arg429Glu
mutant were present at the plasma membrane (Ogiso et al.,
2002). In our experiments, we found that inhibition of
endocytosis promoted levels of mutant EGFR at the cell
surface. We hypothesize that the mutant receptor is unstable
and rapidly undergoes internalization from the plasma
membrane, perhaps implicating altered intracellular protein
binding and subsequent aberrant tethering within membrane
microdomains.
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Figure 4. The mutation in EGFR reduces signal transduction and cell proliferation. (a) Western blotting was performed for p-EGFR, EGFR, p-ERK, ERK, p-Akt, and
Akt on lysates from untransfected (U), wild-type (WT) EGFR, or mutant EGFR (MUT) transfected MCF-7 cells after EGF stimulation for the indicated times. MCF-7
cells express very low endogenous EGFR and therefore EGFR is undetectable in UT cells. Arrows indicate phospho and total EGFR species in top and second row
blots, respectively. Note that the higher-molecular-weight species of EGFR in the WT samples in the second row blot are phosphorylated receptor and directly
correlate with phosphorylated EGFR as detected in the top row blot. (b) Cell proliferation was quantified in CHO-K1 cells transfected with green fluorescent protein
(GFP), WT EGFR-GFP, or mutant EGFR–GFP in starved ( ), normal growth (10% fetal calf serum), or EGF-stimulated (EGF) conditions. (c) GFP-positive cells were
counted and normalized against total cell number, and the cell growth rate was then calculated from these data.
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Functionally, failure of EGFR to correctly localize to cell
membrane is expected to reduce ligand binding. In healthy
people, several ligands require proteolytic cleavage to become
capable of binding to EGFR—this ectodomain shedding is
induced by at least five different metalloprotease enzymes,
including ADAM17 (Blobel, 2005)—mutations in which may
underlie an inflammatory skin and bowel disease that has
overlap with the clinical features present in our patient
(Blaydon et al., 2011). We hypothesize that the lack of
EGFR localization at the cell membrane in our patient has
some similarity at a signaling level to that which occurs in the
ADAM17-deficient patients, i.e., a common failure of EGFR–
ligand interaction and altered downstream signal transduction.
Clinicopathologic similarities with mouse models of EGFR
impairment
The clinical manifestations of the mutation p.Gly428Asp in
terms of loss of EGFR function show some similarities with the
phenotype of Egfr-knockout or transgenic mice (Miettinen
et al., 1995; Sibilia and Wagner, 1995; Threadgill et al.,
1995; Schneider et al., 2008). Although the phenotype of Egfr-
deficient mice depends on the strain of the mice (several are
embryonic lethal), the abnormalities in the skin, lung, and
bowel in surviving mice are similar to many of the clinical
manifestations in our patient. In the epidermis, some knockout
mice show an initially thin skin that then becomes thicker but
with defective barrier function (Miettinen et al., 1995). Lack
of Egfr in mice also affects hair growth, with wavy or reduced
hair growth; EGFR is essential for normal hair follicle
progression through the anagen, catagen, and telogen phases
of the hair growth cycle (Hansen et al., 1997; Schneider et al.,
2008). EGFR initiates hair growth and hair follicle
organization, and EGFR inhibition leads to inflammation,
follicular necrosis, and alopecia, as well as slow hair growth
with brittle hairs, as observed in our patient (Hansen et al.,
1997; Schneider et al., 2008). Egfr-deficient mouse lungs show
condensed collapsed alveoli with a lack of surfactant leading
to respiratory difficulty that has been likened to human
neonatal respiratory distress syndrome (Miettinen et al.,
1995). In murine bowel lacking Egfr, there are fewer, shorter
intestinal villi, and a reduced proliferation of jejunal
enterocytes leading to fluid loss (Miettinen et al., 1995).
Other abnormalities noted in the mice that show phenotypic
similarities to our patient have included cystic dilatation of the
collecting ducts in the kidneys (indicating that EGFR is vital for
the differentiation of structures derived from the ureteric bud),
aortic narrowing, and a thrombotic tendency (Miettinen et al.,
1995). In addition, there are similarities in the phenotype of
transgenic Egfr and Adam17 mice, thus supporting the clinical
overlap in humans with germline autosomal recessive
mutations in EGFR or ADAM17 (Peschon et al., 1998).
Clinical resemblance to the side effects of EGFR inhibitor
medications
The clinical manifestations in the child homozygous for
p.Gly428Asp in EGFR also show some resemblance to the
side effect profile in individuals taking EGFR inhibitors. The
side effects of these drugs include a distinctive acne-like rash
with pustules, dry skin, alopecia, trichomegaly, as well as
mucositis, diarrhea, and, in rare instances, interstitial lung
disease (Inoue et al., 2003; Lacouture, 2006). All these clinical
features were evident to some degree in our patient.
Nevertheless, although skin papules and pustules developed
during disease progression in our case, the early skin changes
mostly consisted of erosions (which led to the erroneous initial
clinical diagnosis of epidermolysis bullosa). EGFR signaling is
known to be involved in the re-epithelialization phase of
wound healing (Repertinger et al., 2004; Pastore et al., 2008),
as well as the proliferation of keratinocyte stem cells (Jensen
et al., 2009), and we hypothesize that the missense mutation
in our patient impeded these processes and was the primary
cause of the erosive skin changes, with bacterial superinfec-
tion being a secondary contributing factor. The transcriptomic
data from our patient illustrate the consequences of impaired
EGFR signaling. The results (albeit based on RNA extracted
from noninflamed skin) reveal enhanced proinflammatory
activation and disturbed differentiation/premature terminal
differentiation of keratinocytes as key pathogenic mechanisms,
thereby demonstrating a similar profile to that associated with
the papulo-pustular rash associated with EGFR inhibitory
drugs (Lacouture, 2006; Lichtenberger et al., 2013; Mascia
et al., 2013). Notably, several inflammatory/innate response
networks were significantly upregulated, including NF-kB.
In conclusion, the EGFR network is one of the most
influential and intricate signaling systems in biology. We
believe the protean features in our patient offer clinical
insights into the critical and diverse roles of EGFR, supporting
many of the putative functions that have been ascribed to the
receptor via murine models and in vitro studies. This case
highlights the major mechanism of epithelial dysfunction
following EGFR signaling ablation and illustrates the broader
impact of EGFR inhibition on other tissues that might be
underappreciated in the context of concurrent malignancy in
patients receiving EGFR inhibitor medications.
MATERIALS AND METHODS
Transmission electron microscopy
Small pieces of skin (o2 mm3) were prepared for transmission
electron microscopy, as described in the Supplementary Material
online.
Immunofluorescence microscopy
A skin biopsy from the affected infant and control skin were collected
in Michel’s medium. The methods for immunofluorescence micro-
scopy and primary antibodies used are listed in the Supplementary
Material online.
Whole-exome sequencing
Initially, 3mg of genomic DNA was sheared with focused acoustic
technology (Covaris, Woburn, MA) to yield a mean fragment size of
150 bp. Fragment ends were repaired and sequencing adaptors
ligated. Biotinylated 120 bp RNA probes (Agilent, Santa Clara, CA),
designed against the coding regions of the genome were hybridized
with the sequence library for 24 hours. DNA bound to RNA probes
was retained using streptavidin-coated magnetic beads; unbound
DNA was washed off. The exome-enriched pool of DNA was eluted
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and amplified with a low-cycle PCR. The DNA fragments were then
sequenced with 100 bp paired-end reads. Novoalign (Novocraft
Technologies, Selangor, Malaysia) was used to align reads to the
reference genome (hg19, National Center for Biotechnology Informa-
tion build 37). With over 7.0 Gb of sequence generated, more than
90% of coding bases of the GENCODE-defined exome were
represented by at least 20 reads (see Supplementary Material online).
Sanger sequencing
We sequenced the exon and intron/exon boundaries of all 28 exons
of EGFR, including the mutation present in exon 11, in the infant,
mother, unaffected older brother, and three controls. Each exon was
amplified by PCR using AmpliTaq Gold 360 Master Mix (Applied
Biosystems, Foster City, CA) and the primers listed in the
Supplementary Material online.
Whole-genome expression microarray analysis
Whole-genome expression microarray analysis was performed using
RNA extracted from skin biopsies sampled from the affected child as
well as four pooled, healthy controls. RNA extraction from cutaneous
biopsies was performed using the Ambion mirVana miRNA Isolation
kit (Invitrogen, Paisley, UK) according to the manufacturer’s instruc-
tions. RNA was amplified using the Illumina TotalPrep RNA
Amplification Kit (Illumina) and subsequent gene expression profiling
was performed using the Illumina array HumanHT-12 v4.0 Expression
BeadChip kit according to the manufacturer’s instructions (Illumina).
Gene expression data were then analyzed using GenomeStudio
software (Illumina). Control samples were pooled and compared with
the affected individual.
Mutant construct transfection
Mutant complementary DNA mimicking the mutation of the infant
(c.1283G4A) was generated with GFP tagged to the C terminus of
EGFR. Wild-type EGFR1-GFP was a gift from Dr Andrew Reynolds
(Institute for Cancer Research, London, UK). The mutant construct
p.Gly428Asp EGFR-GFP was generated using a site-directed muta-
genesis kit (Stratagene, La Jolla, CA) as per the manufacturer’s
instructions using the following mutagenesis primer: 50-GAGAACCT
AGAAATCATACGCGACAGGACCAAGCAACATGGT-30. The muta-
tion in the plasmid was verified by sequencing. Transfection was
carried out using Fugene (Roche Applied Science, Penzberg, Germany)
or Lipofectamine (Invitrogen) reagents according to the manufac-
turers’ instructions.
Confocal microscopy
For confocal microscopy, cultured MCF-7 human breast adenocarci-
noma cells were transfected with wild-type EGFR-GFP or
p.Gly428Asp EGFR-GFP washed with phosphate-buffered saline,
fixed with 4% paraformaldehyde in phosphate-buffered saline for
10 minutes, and then permeabilized with 0.2% TritonX-100 for
10 minutes. For EGF stimulation experiments, cells were incubated
in serum-free medium (Opti-MEM; Gibco Life Technologies, Carls-
bad, CA) for 16 hours before stimulation with 100 ng ml 1 EGF for
the indicated times. For endocytosis inhibition experiments, cells
were treated for 1 hour with 10mM Dynasore (Millipore, Billerica,
MA) or equivalent volume of DMSO as a control before fixation.
Where appropriate, cells were incubated with a primary antibody
directed against the extracellular domain of EGFR for 2 hours
followed by the relevant secondary antibodies conjugated to Alexa-
fluor-568 (Life Technologies, Paisley, UK) and phalloidin conjugated
to Alexafluor-568 or 633 for 1 hour at room temperature.
Western blotting
Thirty thousand MCF-7 or CHO cells per condition were cultured in
either DMEM alone or DMEM containing 10% fetal calf serum (10%
FCS) and transfected with wild-type EGFR-GFP or p.Gly428Asp
EGFR-GFP; 36 hours later, the cells were starved for 16 hours with
Opti-MEM (Gibco Life Technologies) before treatment with
100 ng ml 1 EGF for the appropriate times. Cells were then lysed
in sample buffer containing 2-mercaptoethanol at room temperature.
Lysates were immediately subjected to SDS–PAGE and blotted using
nitrocellulose membrane. Blots were blocked and probed using
p-ERK, ERK, p-Akt, Akt, p-EGFR, and EGFR antibodies (Cell Signaling
Technology, Beverly, MA), as well as HSC-70 antibodies (Santa Cruz
Biotechnology, Dallas, Texas), using 3% milk/phosphate-buffered
saline–0.2% Tween or 5% BSA/TBS-0.1% Tween.
Growth assessment rates
Ten thousand CHO cells per condition were cultured in DMEM
containing 10% FCS for 24 hours before transfection with GFP alone,
wild-type EGFR-GFP, or p.Gly428Asp EGFR-GFP. Twenty-four hours
later, the medium was replaced with normal growth medium (10%
FCS), growth medium minus FCS, or growth medium minus FCS
supplemented with 100 ng ml 1 EGF. Cells were then either Hoechst
treated and fixed immediately with 4% paraformaldehyde or were
fixed 24 hours later. Phase and Hoechst images of five fields of view
per condition were taken using an Olympus IX71 wide-field micro-
scope with a 4 0.13 numerical aperture air objective (Olympus,
Tokyo, Japan). Images were then analyzed for total number of cells as
well as GFP-expressing cells. The number of GFP-expressing cells
was then normalized using the total number of cells per field of view
and presented either as the average number of GFP-expressing cells
per condition or the growth rate per condition.
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